Eqis Capital Management, Inc. Invitae Corp Transaction History

Eqis Capital Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.72 $1,015 - $1,740	-2,417 Reduced 13.3%	15,750 $9,000
Q3 2023 Nov 13, 2023	BUY	$0.6 - $1.53 $10,900 - $27,795	18,167 New	18,167 $10,000
Q1 2023 May 15, 2023	SELL	$1.2 - $2.73 $2,337 - $5,318	-1,948 Reduced 7.58%	23,737 $32,000
Q4 2022 Feb 14, 2023	SELL	$1.71 - $3.61 $2,814 - $5,942	-1,646 Reduced 6.02%	25,685 $47,000
Q3 2022 Oct 24, 2022	BUY	$1.9 - $8.63 $31,988 - $145,294	16,836 Added 160.42%	27,331 $67,000

Q2 2022 Aug 08, 2022	SELL	$2.13 - $9.01 $5,748 - $24,317	-2,699 Reduced 20.46%	10,495 $25,000
Q1 2022 May 16, 2022	SELL	$6.28 - $15.59 $92,755 - $230,264	-14,770 Reduced 52.82%	13,194 $105,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $28.67 $311,331 - $607,201	-21,179 Reduced 43.1%	27,964 $427,000
Q3 2021 Nov 12, 2021	BUY	$24.31 - $33.6 $914,104 - $1.26 Million	37,602 Added 325.81%	49,143 $1.4 Million
Q2 2021 Aug 12, 2021	BUY	$26.09 - $40.4 $22,072 - $34,178	846 Added 7.91%	11,541 $389,000
Q1 2021 May 14, 2021	BUY	$33.06 - $56.93 $353,576 - $608,866	10,695 New	10,695 $409,000

7.66M

Ticker NVTA
Exchange NYSE
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 235,266,000
Description
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.